Efinopegdutide
Sources
registry, as of 2025-02-26Stale
https://clinicaltrials.gov/study/NCT06701305
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015). Overall status COMPLETED. Phases PHASE1. Lead sponsor Merck Sharp & Dohme LLC. Enrollment 48. Conditions Healthy. The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses
ClinicalTrials.gov NCT06701305 protocol and results modules
publication, as of 2023-09-18Stale
https://pubmed.ncbi.nlm.nih.gov/37355043/
patients with non-alcoholic fatty liver disease. This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD). This was a phase IIa, randomize
PMID 37355043